Cadila - Moneycontrol

10
bep
ZU74
HP
7 b'41
hax
Zydus
page
CIN·L24230GJ1996PLC02661t
dedicated 4.61
lou/0
1
Cadila
Healthcare Limited
Regd. Office:
I.
Fax
: +91-79-2686 2368
www.zyduscadila.com
September 15, 2014
Bombay Stock Exchange Limited
li Floor, Pj. Towers
Dalal Street
MUMBAI-400001
National Stock Exchange of India Ltd.
th
Exchange Plaza, 5 Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra (East)
Mumbai - 400051
Kind Attn.. Mr. Sanjay Golecha
Mr. Gopalkrishnan
Kind Attn.: Famroze Pochara
Asst. Vice President
/
-
Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad - 380015
Re.:
Press Release.
Dear Sir/ Madam
We enclose herewith a copy of press release dated September 15, 2014 under the title
manufacture breakthrough
"Zydus and Gilead Enter into a Generic Licensing Agreement to
treatment for Hepatitis C" to be released in the News Papers which gives the full details of
the same.
Please bring the aforesaid news to the
investors at large.
Thanking you,
Yours faithfully,
F R CADILA HEALTHCARE LIMITED
4
UPEN H. SHAH
COMPANY SECRETARY
Encl.: As above.
notice of the members of the exchange and the
15 Sep 2014 16:41 HP Fax
page
2
Zydus
esa Release
Press Release
Press Release
dedicatrel PPiess Release
Press Release
Press Release
1
:-:''
.
.
.
,f
,/.. E'' ' . . . .
f·"..'i:i.'
.:. /:. :'.:....
ZYDUS AND GILEAD ENTER INTO A GENERIC LICENSING AGREEMENT TO MANUFACTURE
BREAKTHROUGH TREATMENT FOR HEPATITIS C
Zydus granted license to produce generic so»birvir ami a single tablet regimen of
ledipasvir/sofosbiwir for treatment of chronic hepatitis C
Ahmedabad, India, September 15, 2014
which will allow
Zydus and Gilead Sciences, Inc. today announced that they signed a non-exclusive licensing agreement
for
ledipasvir/sofosbuvir
tablet
of
regimen
the generic manufacture of sofosbuvir and the investigational single
distribution in 90 developing countries, including India.
There are nearly 10 million patients suffering from hepatitis C in India. The problem is further compounded by the fact
that patients remain undiagnosed till the late stage and can ill afford the treatment.
the Zydus group, Mr. Pankaj R. Patel said, 'By
Speaking on the development, Chairman and Managing Director of
taking
a far reaching step towards fighting the scourge of
are
therapy,
we
joining haiids and providing access to affordable
hepatitis C. This is a laudable initiative on the part of Gilead to make this breakthrough therapy accessible. It is through
such joint initiatives and combined efforts that we serve the cause of healthcare. Bridging healthcare gaps and serving
critical patient needs with access to new therapies have always been our mi ssion and we stand committed to this."
Zydus Heptiza, the specialty division ofthe Zydus group which will be marketing the therapy has been solely focused on
division
improving treatment access in Chronic Viral Hepatitis. Over the last four years since launch, Heptiza is the only
out to
reaching
been
has
Ir
Iiidia.
in
management
C
hepatitis
B
&
approved
for
present with an entire range of antivirals
high risk population with free screening for hepatitis B & C patients and has made available hepatitis B vaccitiation to
patients, free of cost.
Under the licensing agreement, Zydus will receive a complete technology transfer of the Gilead manufacturing process to
enabling production to be scaled up as quickly as possible. Zydus will set its own prices for the generic product, paying a
royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other
business essential activities. The licenses also permit the manufacture of sofosbuvir or lodipasvir in combination with
other chronic hepatitis C medicines.
Sofosbuvir was approved under the trade name Sovaldi® by the U.S. Food and Drug Administration (FDA) in December
2013 alid by the European Commission in January 2014. The FDA and the European Medicines Agency are currently
reviewing the company' s applications for a single tablet regimen of ledipasvir/sofosbuvir; it is an investigational agent and
its safety and efficacy have not been established.
About Zydus Cadila
Zydus Ca(lila is an innovative, global pharmaoeutioal company that discovers. develops, manufactures and markets a
broad range of healthcare therapies. The group employs over 16,000 people worldwide aiid is dedicated to creating
healthier communities globally. Zydus Cadila is the only Indian pharma company to launch its own patented N CE Lipaglyn™, the world's first drug to be approved for tbe treatment of diabetic dyslipidemia. It aims to be a leading global
healthcare provider with a robust product pipeline, achieve sales of over Rs. 10000 crore by 2015 and be a research-based
pharmaceutical company by 2020,
###
1
1
For fullher Information please contact ,
The Corporate Communications Department
I
Ca(lila Healthcare Limited
i 'Zydus Tower, Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 20 lines) Fax : +91-79-2686 2365 www.zyduscadila.com
C025878
CIN·L24230GJ1995PL

Download Report